Correlation Between Opthea and Neurobo Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Opthea and Neurobo Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Opthea and Neurobo Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Opthea and Neurobo Pharmaceuticals, you can compare the effects of market volatilities on Opthea and Neurobo Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Opthea with a short position of Neurobo Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Opthea and Neurobo Pharmaceuticals.

Diversification Opportunities for Opthea and Neurobo Pharmaceuticals

0.05

Correlation Coefficient

Opthea  Neurobo Pharmaceuticals

Significant diversification

The 3 months correlation between Opthea and Neurobo is 0.05. Overlapping area represents the amount of risk that can be diversified away by holding Opthea and Neurobo Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Neurobo Pharmaceuticals and Opthea is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Opthea are associated (or correlated) with Neurobo Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Neurobo Pharmaceuticals has no effect on the direction of Opthea i.e., Opthea and Neurobo Pharmaceuticals go up and down completely randomly.

Pair Corralation between Opthea and Neurobo Pharmaceuticals

Considering the 90-day investment horizon Opthea is expected to generate 0.74 times more return on investment than Neurobo Pharmaceuticals. However, Opthea is 1.36 times less risky than Neurobo Pharmaceuticals. It trades about 0.15 of its potential returns per unit of risk. Neurobo Pharmaceuticals is currently generating about -0.06 per unit of risk. If you would invest  333.00  in Opthea on November 27, 2024 and sell it today you would earn a total of  138.00  from holding Opthea or generate 41.44% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	71.19%
Values	Daily Returns

Opthea  vs.  Neurobo Pharmaceuticals

Opthea

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Opthea are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Opthea unveiled solid returns over the last few months and may actually be approaching a breakup point.

Neurobo Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Opthea and Neurobo Pharmaceuticals

The main advantage of trading using opposite Opthea and Neurobo Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Opthea position performs unexpectedly, Neurobo Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will offset losses from the drop in Neurobo Pharmaceuticals' long position.

The idea behind Opthea and Neurobo Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.